CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

Japanese researchers have used a nimble robotic hand exoskeleton to train expert pianists to improve their performance, using ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent ...

Takeda’s plasma-derived therapies (PDT) business tackles supply-chain challenges to expand access to life-saving treatments, ...

Haemonetics updated its hospital revenue guidance to 24% to 26% reported growth and 12% to 14% organic growth, driven by strong adoption of hemostasis cartridges and vascular closure devices.

Carlisle Companies Incorporated (NYSE:CSL) today announced it has completed the previously announced purchase of Texas-based expanded polystyrene insulation manufacturer ThermaFoam.

Q3 2025 Earnings Call Transcript February 6, 2025 Operator: Good day, and welcome to the Haemonetics Third Quarter Fiscal ...

Q4 2024 Earnings Call Transcript February 4, 2025 Carlisle Companies Incorporated beats earnings expectations. Reported EPS ...

Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful ...

The ASX200 closed slightly higher amid mixed profit results, but gold stocks lifted as global trade uncertainty increased.

A weak vaccine result dragged on CSL's H1 result but analysts focus on an improving plasma product margin and solid growth ...

UBS believes the CSL shares story is "heavily focused on gross profit margin improvement" at Behring. According to CSL, that division develops and delivers "high-quality medicines that treat ...